alexsl
- Nanocap pharma company Eyenovia (NASDAQ:EYEN) lost more than two-thirds of its market value on Friday after announcing that its drug-device combination containing low-dose atropine failed in a Phase 3 trial for children with myopia (nearsightedness).
- Citing an analysis conducted by